Cyclic intravenous pamidronate for an infant with osteogenesis imperfecta type II.

BMJ Case Rep

Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Published: May 2023

A woman in her 30s underwent a 17-week ultrasound which revealed short bowed long bones. Fetal CT at 28 weeks' gestation showed decreased ossification of the skull, a small bell-shaped thorax, hypoplastic vertebrae, and shortening and bowing of the long bones, leading to the diagnosis of osteogenesis imperfecta (OI) type II. The newborn was delivered via caesarean delivery, and tracheal intubation was performed due to the respiratory distress. A heterozygous variant in (c.1679G>T, p. Gly358Val) was ascertained, confirming the diagnosis of OI type II.Cyclic intravenous pamidronate was started at 41 days old with dose modification and was successfully administered every month. Currently, the infant is 8 months old without any new bone fracture. He was extubated successfully at 7 months of age and is now stable using high flow nasal cannula. The efficacy, safety, and optimal dose and timing of cyclic pamidronate for OI type II remain undefined. We report our experience of successful cyclic intravenous pamidronate treatment for an infant with OI type II.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186469PMC
http://dx.doi.org/10.1136/bcr-2022-252593DOI Listing

Publication Analysis

Top Keywords

intravenous pamidronate
12
cyclic intravenous
8
osteogenesis imperfecta
8
imperfecta type
8
long bones
8
type
5
pamidronate
4
pamidronate infant
4
infant osteogenesis
4
type woman
4

Similar Publications

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication associated with the use of antiresorptive agents, impacting patient quality of life and treatment outcomes. Predictive modeling may aid in a better understanding of MRONJ development.

Purpose: The study aimed to evaluate machine learning (ML)-based models for predicting MRONJ in patients receiving antiresorptive therapy.

View Article and Find Full Text PDF

Post-transplant hyperparathyroidism (PT-HPT) is common in kidney transplant recipients (KTRs) and can cause nephrocalcinosis and graft dysfunction. Cinacalcet is commonly used for treating PT-HPT but may induce calciuria and exacerbate nephrocalcinosis. The concurrent use of bisphosphonates with cinacalcet to prevent this complication has not been reported.

View Article and Find Full Text PDF
Article Synopsis
  • - Vitamin D toxicity is uncommon but can cause serious health issues, including high calcium levels in the blood (hypercalcemia) and complications like kidney failure and heart problems.
  • - A case study of a 76-year-old man highlights the dangers of excessive long-term vitamin D use from supplements, leading to severe hypercalcemia and kidney injury.
  • - The patient was treated with intravenous fluids and medications, including pamidronate, which ultimately helped improve his high calcium levels and kidney function.
View Article and Find Full Text PDF

Generalized arterial calcification of infancy (GACI) is a rare disease characterized by arterial calcification. GACI is caused by a mutation in the ENPP1 or ABCC6 genes. GACI causes severe hypertension and heart failure, and approximately 50% of patients die within the first 6 months.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!